Brought to you by:
First-in-man results to show promise for robot-assisted HIFU in PAD treatment
Results of a first-in-human study of non-invasive, robotic-assisted high intensity focused ultrasound (HIFU) for the treatment of peripheral arterial disease (PAD), to be presented Friday morning, will show that the therapy appears to be safe and feasible for the treatment…
Sonovein FDA pivotal study treatments completed: Theraclion reaches key milestone on schedule
Theraclion, a French MedTech company developing a robotic platform for non-invasive high-intensity focused ultrasound (HIFU) therapy, announces today that treatments in the Food and Drug Administration (FDA) pivotal study for Sonovein, an extracorporeal medical device made to treat varicose veins using…
FDA approves IDE for pivotal study of high-intensity focused ultrasound platform
The Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) application for the VEINRESET multicenter pivotal study that will evaluate Sonovein high-intensity focused ultrasound (HIFU) treatment for varicose veins, it has been announced. Antonios Gasparis, MD, director…
AVF 2023: Results from first US trial of Sonovein delivered
The 2023 annual meeting of the American Venous Forum (AVF) heard the final results from the first U.S. trial of the emerging varicose vein treatment, Sonovein echotherapy, with data showing a 100% technical feasibility at three months—which was the principal…